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sensitivity and prevents the progression of heart
failure in senescent beagles
Melissa Chen1, Franca S Angeli1, You-tang Shen1 and Richard P Shannon1,2,3*Abstract
Background: We previously demonstrated that older beagles have impaired whole body and myocardial insulin
responsiveness (MIR), and that glucagon-like peptide-1 (GLP-1 [7–36] amide) improves MIR in young beagles with
dilated cardiomyopathy (DCM). Here, we sought to determine if aging alone predisposes to an accelerated course
of DCM, and if GLP-1 [7–36] amide would restore MIR and impact the course of DCM in older beagles.
Methods: Eight young beagles (Young-Control) and sixteen old beagles underwent chronic left ventricle (LV)
instrumentation. Seven old beagles were treated with GLP-1 (7–36) amide (2.5 pmol/kg/min) for 2 weeks prior to
instrumentation and for 35 days thereafter (Old + GLP-1), while other 9 served as control (Old-Control). All dogs
underwent baseline metabolic determinations and LV biopsy for mitochondria isolation prior to the development
of DCM induced by rapid pacing (240 min−1). Hemodynamic measurements were performed routinely as heart
failure progressed.
Results: At baseline, all old beagles had elevated non-esterifed fatty acids (NEFA), and impaired MIR. GLP-1 reduced
plasma NEFA (Old-Control: 853 ± 34; Old + GLP-1: 531 ± 33 μmol/L, p < 0.02), improved MIR (Old-Control: 289 ± 54;
Old + GLP-1: 512 ± 44 mg/min/100 mg, p < 0.05), and increased uncoupling protein-3 (UCP-3) expression in isolated
mitochondria. Compared to the Young-Control, the Old-Controls experienced an accelerated course of DCM (7 days
versus 29 days, p < 0.005) and excess mortality, while the Old + GLP-1 experienced increased latency to the onset of
DCM (7 days versus 23 days, p < 0.005) and reduced mortality.
Conclusion: Aging is associated with myocardial insulin resistance, which predispose to an accelerated course of
DCM. GLP-1 treatment is associated with increased MIR and protection against an accelerated course of DCM in
older beagles.
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The aging population in the western world continues to
be burdened by a disproportionate share of cardiovascu-
lar (CV) disease and the morbidity and mortality of car-
diovascular conditions such as heart failure is increased
among the elderly [1,2]. Cardiovascular risk factors such
as hypertension and diabetes accrue in older populations
contributing to the increased burden of CV disease.* Correspondence: rs3mt@virginia.edu
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unless otherwise stated.However, it remains uncertain as to how much of the
burden is a consequence of these recognized risk factors
and how much is attributable to aging alone [3].
Prior studies from our laboratory have demonstrated
that aging in beagles is associated with the development
of both whole body and myocardial insulin resistance,
independent of obesity or inactivity [4]. Other studies
have demonstrated similar findings in rodents with a
greater emphasis on skeletal muscle insulin resistance than
on myocardial insulin resistance [5]. However, myocardial
insulin resistance may be of clinical importance, given the
preference for stressed heart to increase glucose utilization
and reduce non-esterifed fatty acids (NEFA) oxidation [6].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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myocardial insulin resistance in senescent beagles is associ-
ated with mitochondrial abnormalities leading to accumu-
lation of unoxidized NEFA in cardiac myocytes [4]. The
mitochondrial abnormalities include decreased expression
of key regulators of oxidative phosphorylation including
mitochondrial cytochrome oxidase-1 (MCO) and uncoup-
ling protein-3 (UCP-3) [6]. Others have shown that senes-
cent cardiac mitochondria have increased generation of
reactive oxygen species leading to peroxidation of key
mitochondrial proteins [7,8] predisposing to mitochondrial
swelling and disruption. Moreover, in the setting of ad-
vanced age, mitochondrial biogenesis, myocyte energetics
and cell survival may be compromised [9-11], contributing
to an increased risk of heart failure in this population [12].
Therefore, new strategies designed to improve mito-
chondrial function and restore myocardial insulin resist-
ance in older patients may prove cardio-protective. One
such candidate is glucagon-like peptide −1 (GLP-1 [7-36]
amide), an incretin hormone that has shown to have
potential cardiovascular benefits beyond glycemic control
[13-18]. We have previous demonstrated that GLP-1
[7-36] amide was associated with increased insulin action
and improved mitochondrial function in young dogs with
pacing induced cardiomyopathy [19]. Accordingly, the
purpose of the present study was to determine if aging
alone predisposes to an accelerated course of dilated
cardiomyopathy (DCM) induced by rapid pacing in the
absence of conventional cardiovascular risks. A second
goal was to determine if myocardial insulin responsive-
ness could be restored in the senescent myocardium
through treatment with GLP-1 (7–36) amide. A third
goal was to determine whether preservation of mito-
chondrial proteins and restoration of myocardial insulin
responsiveness would protect the older beagles from an
accelerated course of DCM when exposed to a similar
pacing stress.Figure 1 Schematic illustration of the study design and time points fo
test; Clamp, hyperinsulinemic-euglycemic clamp.Methods
Eight young (Young-Control; age 3 years) and 16 old
(10–12 years) beagles, weighing 14–18 kg were used in
the present study. Figure 1 summarizes the study design.
Animal age was confirmed through dental examinations
by the veterinary staff. All dogs were carefully screened
for all disease known to occur commonly in canines and
studied in accordance with the “Guide for the Care and
Use of Laboratory Animal Resources” [DHHS Publica-
tion No (NIH) 86–23, Revised 1996] and the guidelines
of the Institutional Animal Care and Use Committees of
the University of Pennsylvania.
Acclimation and surgical instrumentation
The animals were acclimated to the research laboratory
for 6 weeks prior to surgical instrumentation. They were
fed a standard chow once daily with a fixed carbohydrate
and fat content, and underwent a supervised exercise regi-
men on a treadmill each day for 30 minutes four times
per week for 6 weeks prior to surgical instrumentation as
previously described [4].
All dogs underwent sterile surgical instrumentation as
previously described [15,20,21]. The dogs were allowed
to recover from the surgical procedure for 7 days, during
which time they were treated with analgesics and antibi-
otics and trained to rest quietly on the experimental
table in a conscious, unrestrained state.
GLP-1 (7–36) amide intervention protocol
After 4 weeks of training, the older dogs were random-
ized to receive either GLP-1 (7–36) amide though a con-
tinuous intravenous infusion at a dose of 2.5 pmol/kg/
min (Old + GLP-1; n = 7) or saline (3 ml/day) control
(Old-Control; n = 9) using a MiniMed infusion system.
The GLP-1 (7–36) amide treatment was initiated 2 weeks
prior to surgery and was continued through surgery, re-
covery (1 week) and during the rapid pacing stimulus forr assessment. LV, left ventricle; IV GTT, intravenous glucose tolerance
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of normal saline and 0.2 ml of fresh plasma prepared
from each animal as previously described [15]. A 99%
pure, pyrogen-free and sterile, single lot of GLP-1 (7–36)
amide synthesized in the protein/peptide core facility of
the Massachusetts General Hospital was used in this
study. Net peptide content was used for all calculations.
Metabolic determinations
All metabolic parameters were measured at 8 am, fol-
lowing an overnight fast. After 4 weeks of training, all
dogs underwent baseline blood sampling and an intra-
venous glucose challenge (250 mg/kg IV with 5–10 mi-
nute sampling of glucose and insulin for 60 minutes) to
determine the magnitude of whole body insulin resist-
ance between young and old beagles prior to exposure
to GLP-1. In addition, plasma norepinephrine, insulin,
glucagon, adiponectin, non-esterified fatty acids (NEFA),
and glucose were measured as previously described [20].
Additionally, whole body and myocardial insulin sensi-
tivity was assessed using the hyperinsulinemic-euglycemic
clamp after surgical instrumentation and prior to the
pacing insult to assess the effects of 3 weeks of GLP-1
treatment [15,19]. Briefly, in the fasting state, a primed,
constant infusion of insulin (480 pmol • m−2 • min−1) was
administered for 120 minutes to create a steady state con-
centration of plasma insulin (~1000 pmol/L). Arterial glu-
cose concentrations were measured every 5 minutes and
glucose was infused to maintain plasma glucose concen-
trations at 5 mmol/L ±5%. Myocardial glucose and NEFA
balance and coronary blood flow were sampled every
15 minutes to determine myocardial glucose uptake.
Trans-myocardial substrate balance was calculated as the
difference between arterial and coronary sinus content.
Basal myocardial substrate uptake was calculated as the
product of myocardial substrate balance and coronary
blood flow (CBF) [15,19].
Induction of dilated cardiomyopathy and hemodynamic
measurements
After baseline metabolic and hemodynamic measure-
ments, all animals underwent rapid right ventricular
pacing using a customized pacemaker at 240 beats/ mi-
nute. The rapid pacing was confirmed daily. Animals
underwent hemodynamic evaluation at baseline (prior
to pacing), daily for the first 3 days after pacing and then
every 3 days for the next 28 days or until pre-specified
hemodynamic parameters indicative of advanced DCM
were reached. Advanced DCM was defined by the presence
of depressed LV contractility (LVdP/dt) <1500 mmHg/sec,
increased LV end-diastolic pressure (LVEDP) > 30 mmHg,
reduced cardiac output (CO) < 1.8 L/min, and increased
LV end-diastolic dimensions (LVEDD) >45 mm. In
addition, stroke volume (SV), and myocardial oxygenconsumption (MVO2) (product of the left circumflex CBF
and the myocardial arterio-venous O2 content difference)
were calculated. Coronary flow reserve (maximal coron-
ary blood flow in response to adenosine- resting CBF,
ml/min) was determined before and after the develop-
ment of DCM.
Mitochondrial isolation
LV myocardial biopsy for isolation of intrafibrillar mito-
chondria (IFM) was performed at baseline during surgical
instrumentation. This timing allowed for comparison of
mitochondrial proteins between Young and Old-Control
and Old +GLP-1 treated beagles. Crude mitochondrial
isolates were prepared from canine myocardium using a
trypsin digestion procedure as described previously [4,15].
Briefly, after confirming the purity of the mitochondrial
preparations by the absence of Na+/K +ATPase activity,
isolated mitochondrial samples were re-suspended to a
final protein concentration of 0.5 μg/mL in a buffer at a
final concentration of 125 mM Tris–HCl, pH 6.8, 20%
(v/v) glycerol, 5% (v/v) β-mercaptoethanol, and 0.1% (w/v)
bromphenol blue. Membrane samples for UCP-3, SDHA,
and MCO were subjected to electrophoretic separation by
SDS-PAGE [4,22]. Proteins resolved were transferred onto
PVDF membrane (Immobilon™-PSQ, Millipore Corp.,
Bedford, MA) at a constant voltage (100 V) [23]. Nonspe-
cific membrane protein binding sites were blocked [5%
(w/v) dry milk in Tris-buffered saline with 0.1% (v/v)
Tween-20 (TTBS)] and then membranes were probed
with polyclonal rabbit anti-UCP-3 antibody (1:10,000)
(Alpha Diagnostics, San Antonio, TX), or monoclonal
mouse anti-MCO antibody (1:100,000) (Abcam Inc.,
Cambridge, MA). The immunoreactive proteins were
detected by use of an enhanced horseradish peroxidase/
luminol chemiluminescence reaction kit (Perkin Elmer Life
Sciences, Boston, MA) and exposed to X-ray film (Hyper-
film ECL™, Amersham Pharmacia Biotech, Piscataway, NJ).
Densitometric analysis of the bands was carried out
using a Personal Densitometer SI and ImageQuant™
Software (Molecular Dynamics, Sunnyvale, CA).
Mitochondrial lipid peroxidation was assessed by levels
of malondialdehyde (MDA), a marker of lipid oxidation
using lipid peroxidation assay kit (Calbiochem, San Diego,
CA) as previously described [24]. To prevent sample
oxidation, extracts were normalized to 1–1.5 mg/ml in
re-suspension buffer with 5 mM butylated hydroxyl
toluene. For each reaction, a 200-μl sample/standard
was added to 650-μl chromogenic reagent and 150 μl of
12 N HCl. After reaction at 45°C for 60 min, the sam-
ples were cooled at 4°C and centrifuged at 10,000 g for
5 min. The supernatants were collected, and absorbance
at 586 nm was recorded. MDA concentration was calcu-
lated using a standard curve. All measurements were
performed in duplicate.
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Data are expressed as the mean value ± SEM. Differences
in hemodynamic and metabolic responses between the
groups were determined by two-way ANOVA. Where
differences were detected over time, a post hoc Student’s
Newman Keuls’s test was performed to determine differ-
ences at respective time points. Differences in mitochon-
drial proteins and metabolic parameters were determined
using Student T-test for unpaired data. A Bonferroni
correction was used when multiple comparisons were
evaluated. A level of p < 0.05 was considered statistically
significant.
Results
The effects of age on baseline body mass index and
metabolic parameters
Table 1 illustrates the effects of age on body mass index
and metabolic parameters after 4 weeks of training and
prior to GLP-1 infusion and surgical instrumentation. At
baseline, there was no difference in body weight, body
mass index or abdominal girth between groups. Fasting
plasma glucose levels were normal while plasma insulin
levels (p < 0.01) and NEFA levels (p < 0.001) were signifi-
cantly higher in the Old-Control and Old +GLP-1 groups
suggesting insulin resistance. There were no differences in
plasma adiponectin or leptin levels. Notably, plasma arter-
ial norepinephrine was also increased (p < 0.001) in the
Old-Control and Old +GLP-1 groups.
The intravenous glucose challenge in young and older
beagles at baseline prior to GLP-1 infusion was associ-
ated with a higher peak plasma glucose response in the
Old-Control and Old + GLP-1 groups (Figure 2A) and a
markedly greater increase in plasma insulin (Figure 2B),
suggesting whole body insulin resistance in the Old-
Control and Old + GLP-1 groups compared to Young-
Control. Notably, there was no difference in the degree
of whole body insulin resistance or any other baselineTable 1 Effects of age on baseline body mass index and meta
Young Old
Control Old-Control
n = 8 n = 9 p
Age (years) 3.5 ± 1 11.2 ± 1 <
BMI (kg/w2) 25 ± 0.6 26 ± 0.7 N
Body Weight (kg) 15 ± 3 15 ± 3 N
Glucose (mmol/L) 5.2 ± 0.2 5.0 ± 0.2 N
NEFA (μmol/L) 363 ± 52 897 ± 67 <
Insulin (pmol/L) 33 ± 9 110 ± 13 <
Glucagon (pq/ml) 26 ± 2 32 ± 9 N
Adiponectin (μg/ml) 2.9 ± 0.6 2.7 ± 0.9 N
NE (pmol/ml) 56 ± 13 396 ± 52 <
Data is presented as Mean ± SEM; *Compared to young; **Old-Control compared to
treated; BMI, body mass index; NEFA, Non-esterified fatty acids; NE, plasma arterialparameter between the Old-Control and Old + GLP-1
groups prior to GLP-1 infusion (Table 1).
Age and the effects of GLP-1Infusion on hemodynamic
parameters prior to onset of pacing induced DCM
After 3 weeks of GLP-1 treatment and 7 days from
surgical instrumentation (Figure 1), LV and systemic
hemodynamics were assessed in all groups (Table 2).
There were no significant differences in the LV systolic
or end diastolic pressures, LV dP/dt, or LV dimensions
between groups. Old-Control beagles had impaired LV
isovolumic relaxation time constants (tau: 25 ± 2 vs.
18 ± 1 msec, p < 0.001), higher mean arterial pressures
(107 ± 7 vs. 89 ± 3 mmHg, p < 0.05) and systemic vascu-
lar resistance (3421 ± 224 vs 2649 ± 267 dyne-sec-cm−5,
p < 0.05) compared to Young-Control, but comparable
heart rate, cardiac output, and LV ejection fraction.
Old-Control dogs had higher resting MVO2 compared
to Young-Control (313 ± 39 vs 150 ± 21 mlO2/min, p <
0.01). GLP-1 treatment improved isovolumic relaxation
in Old + GLP-1 compared to Old-Control (p < 0.05).
GLP-1 had no significant effects on resting cardiac out-
put or coronary blood flow. Mean arterial pressure, sys-
temic vascular resistance and MVO2 tended to be lower
in Old + GLP-1 dogs after 3 weeks of treatment com-
pared to Old-Control, although the differences did not
reach statistical significance.
Age predisposes progression of pacing induced DCM
Figure 3 illustrates the time course of the development of
hemodynamically significant dilated cardiomyopathy fol-
lowing the initiation of rapid pacing. LV dP/dt decreased to
less than 1,500 mmHg/sec within 7 days in Old-Control
dogs compared to 25 days in Young-Control (p < 0.001,
Figure 3A). Cardiac output declined to less than 1.7 l/min
within 3 days in Old-Control compared to 28 days in
Young-Control (p < 0.001, Figure 3B), while LV endbolic parameters
Old + GLP-1
value* n = 7 p value* p value **
0.01 11.9 ± 1 <0.01 NS
S 27 ± 1 NS NS
S 16 ± 2 NS NS
S 4.9 ± 0.3 NS NS
0.01 913 ± 75 <0.01 NS
0.01 99 ± 20 <0.01 NS
S 38 ± 8 NS NS
S 2.9 ± 0.5 NS NS
0.01 422 ± 40 <0.01 NS
Old + GLP-1; Old-Control, old beagles placebo; Old + GLP-1, old beagles GLP-1
norepinephrine.
Figure 2 Baseline intravenous glucose challenge 4 weeks after training. Young-Control (n = 8), Old-Control (n = 9), and Old + GLP-1 (n = 7)
dogs underwent to an intravenous glucose challenge prior to randomization to GLP-1 infusion. (A) Higher peak of plasma glucose response
and (B) greater increase in plasma insulin in the older dogs, both suggesting whole body insulin resistance in the older groups compared to
Young-Control animals. IV GTT, intravenous glucose tolerance test; *p < 0.01.
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7 days in Old-Control compared to 28 days in Young-
Control (p < 0.001, Figure 3C). Finally, LV dilatation
occurred within 3 days in Old-Control compared to
28 days in Young-Control (p < 0.001, Figure 3D). Not-
ably, 33% (n = 3) of the Old-Control dogs died before
reaching the pre-specified hemodynamic end point com-
pared to 0% mortality in the Young-Control at 28 days.
Thus, despite comparable baseline hemodynamics, Old-
Control dogs had a remarkably accelerated course of
pacing induced DCM.
GLP-1 infusion restores myocardial substrate uptake in
older dogs
The beneficial effects of GLP-1 infusion on myocardial
metabolism were assessed under conditions of thehyperinsulinemic-euglycemic clamp. Both basal and in-
sulin stimulated myocardial glucose uptake were re-
duced in Old-Control dogs (Figure 4A) while basal
myocardial NEFA uptake was increased compared to
Young-Control (Figure 4B). Hyperinsulinemia suppressed
myocardial NEFA uptake and to a greater extent in Old-
Control compared to Young-Control (Figure 4B). In
contrast, GLP-1 infusion improved basal and insulin stim-
ulated myocardial glucose uptake in Old +GLP-1 and
suppressed basal NEFA uptake compared to Old-Control
dogs (Figure 4A).
Moreover, GLP-1 infusion had a positive impact on re-
active oxygen species and mitochondrial protein expres-
sion in Old +GLP-1. Aging was associated with increased
cellular and mitochondrial reactive oxygen species (ROS)
compared to Young-Control as demonstrated by higher
Table 2 Aging and GLP-1 on left ventricular and systemic hemodynamics after 3 weeks of GLP-1 treatment and
before the onset of DCM
Young Old
Control Old-Control Old + GLP-1
n = 8 n = 9 p value* n = 7 p value*
LVESP ( mmHg) 118 ± 4 132 ± 10 NS 130 ± 10 NS
LVEDP (mmHg) 9 ± 1 11 ± 2 NS 10 ± 3 NS
LV dP/dt ( mmHg /sec) 2881 ± 121 2801 ± 176 NS 2912 ± 200 NS
LV tau (msec) 18 ± 1 25 ± 2 <0.01 19 ± 1† NS
MAP ( mmHg) 89 ± 3 107 ± 7 <0.05 102 ± 5 <0.05
Heart Rate (min-1 ) 90 ± 4 101 ± 10 NS 99 ± 12 NS
CO (L/min) 2.7 ± 0.3 2.5 ± 0.3 NS 2.5 ± 0.4 NS
LVEF (%) 54 ± 4 50 ± 5 NS 51 ± 4 NS
SVR (dyne-sec-cm-5) 2649 ± 267 3421 ± 224 <0.05 3164 ± 123 NS
MVO2 (ml O2/min) 150 ± 21 313 ± 39 <0.01 243 ± 22† <0.01
Coronary Flow (ml/min) 25 ± 3 26 ± 4 NS 27 ± 4 NS
LVEDD (mm) 40 ± 3 40 ± 3 NS 41 ± 3 NS
LVESD (mm) 33 ± 2 34 ± 3 NS 33 ± 3 NS
Data is presented as Mean ± SEM; *Compared to young; † p < 0.05 compared to Old-Control; Old-Control, old dogs placebo; Old + GLP-1, old dogs GLP-1 treated;
LVESP, left ventricle end-systolic pressure; LVEDP, left ventricle end-diastolic pressure; LV dP/dt, left ventricle rate of rise of left ventricular pressure; tau, isovolumic
relaxation time constants; MAP, mean arterial pressure; CO, cardiac output; LVEF, left ventricle ejection fraction; SVR, systemic vascular resistance; MVO2, myocardial
oxygen consumption, LVEDD, left ventricle end-diastolic diameter; LVESD, left ventricle end-systolic diameters.
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Control dogs (Figure 5A). Aging was also associated with
decreased mitochondrial expression of UCP-3 and MCO
in cardiomyocytes compared to Young-Control (Figure 5B).
Interestingly, GLP-1 infusion increased mitochondrial
protein expression and decreased MDA abundance com-
pared to Old-Control suggesting that GLP-1 may amelior-
ate underlying mitochondrial protein abnormalities and
reduce ROS observed in the cardiomyocytes with aging.GLP-1 infusion preserves coronary flow reserve
There were no differences in basal coronary blood flow
responses between groups either before (Figure 6A) or
after the development of DCM (Figure 6B). However,
the vasodilator response to hyperinsulinemia was mark-
edly attenuated in Old-Control dogs at baseline and abol-
ished completely following the development of DCM
(Figure 6B). Notably, Old +GLP-1 dogs demonstrated
preserved coronary vasodilator response to hyperinsuline-
mia in the basal state, but not following the development
of advanced DCM (Figure 6A and B). Similarly, the cor-
onary blood flow response to adenosine was reduced in
Old-Control dogs both under basal conditions and fol-
lowing DCM (Figure 6C and D). Interestingly, Old +
GLP-1 dogs showed preserved flow reserve under basal
conditions and better preservation of flow reserve fol-
lowing the development of DCM compared to Old-
Control (Figure 6C and D).GLP-1 protects old beagles from an accelerated course of
DCM
GLP-1 infusion and the associated improvement in myo-
cardial insulin action, mitochondrial protein expression
and coronary flow reserve was associated with a prolonged
course of dilated cardiomyopathy and increased survival
in Old + GLP-1 compared to Old-Control (Figure 7). LV
dP/dt decreased to less than 1,500 mmHg/sec within
7 days in Old-Control dogs with myocardial insulin resist-
ance compared to 24 days in Old +GLP-1 dogs (p < 0.01,
Figure 7A). Cardiac output declined to less than 1.7 l/min
within 3 days in Old-Control compared to 28 days in
Old + GLP-1 dogs (p < 0.01, Figure 7B), while LV end
diastolic pressure rose to greater than 30 mmHg within
7 days in Old-Control compared to 21 days in Old +
GLP-1 dogs (p < 0.01, Figure 7C). Finally, LV dilatation
occurred within 3 days in Old-Control compared to
28 days in Old + GLP-1 dogs (p < 0.001, Figure 7D). Inter-
estingly, Old + GLP-1 dogs survived to 28 days similar to
that seen in Young-Control, but in contrast to the prema-
ture mortality observed in Old-Control. Compare to
Young-Control (Figure 3) Old +GLP-1 dogs did not differ
statistically in any of the hemodynamic parameters during
the progression of pacing induced DCM.Discussion
In the present study, we observed that old dogs with myo-
cardial insulin resistance developed an accelerated course
Figure 3 The effects of aging infusion on the time course to the development of DCM. Despite comparable baseline hemodynamics,
Old-Control had a remarkably accelerated course of pacing induced DCM compared to Young-Control as demonstrated by: (A) early drop of
LV dP/dt and (B) cardiac output, (C) rapid rise of LVEDP, and (D) early enlargement of left ventricle. LV dP/dt, left ventricle rate of rise of left
ventricular pressure; LVEDP, left ventricle end-diastolic pressure; LVEDD, left ventricle end-diastolic diameter.
Figure 4 Effects of age and GLP-1 infusion on myocardial glucose and non-esterified fatty acids uptake. GLP-1 treatment improved basal
and insulin stimulated myocardial glucose uptake (A) and suppressed basal NEFA uptake compared to Old-Control dogs (B). NEFA, non-esterified
fatty acids; *Old-Control versus Old + GLP-1, p < 0.05; # Old-Control versus Young-Control #p < 0.01.
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Figure 5 Effects of age and GLP-1 infusion on reactive oxygen species and mitochondrial protein expression. Aging was associated with
higher levels of malondialdehyde (A) and decreased mitochondrial expression of UCP-3 and MCO (B) compared to Young-Control.
GLP-1 treatment decreased malondialdehyde abundance (A) and increased mitochondrial protein expression (B) in Old + GLP-1 compared to
Old-Control. MCO, mitochondrial cytochrome oxidase-1; UCP-3, uncoupling protein-3. *Old-Control versus Old + GLP-1, p < 0.05; #Old-Control
versus Young-Control #p < 0.01.
Figure 6 Basal and provoked coronary blood flow responses before and after pacing. Basal and provoked coronary blood flow in response
to hyperinsulinemia pre-pacing (A) and after onset of dilated cardiommyopathy (B). Basal and provoked coronary blood flow in response to and
near maximal coronary vasodilator doses of adenosine pre pacing (C) and at the onset of dilated cardiomyopathy (D). # p < 0.01 compared to
baseline and to Old-Control.
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Figure 7 The Effects of GLP-1 infusion on the time course to the development of DCM. Despite comparable baseline hemodynamics,
Old-Control had a remarkably accelerated course of pacing induced DCM compared to Old + GLP-1 as demonstrated by: (A) early drop of LV
dP/dt and (B) cardiac output, (C) rapid rise of LVEDP, and (D) early enlargement of left ventricle. LV dP/dt, left ventricle rate of rise of left
ventricular pressure; LVEDP, left ventricle end-diastolic pressure; LVEDD, left ventricle end-diastolic diameter.
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pacing compared to Young-Control. Treatment with a
continuous infusion of GLP-1(7–36) amide improved
myocardial insulin sensitivity, reduced myocardial mito-
chondrial oxidative stress, preserved expression of key
mitochondrial proteins associated with oxidative bal-
ance (UCP-3) and mitochondrial respiration (MCO),
and preserved coronary flow reserve culminating in an
improved clinical course and reduced mortality following
rapid pacing. These findings underscore the role of mito-
chondrial dysfunction and associated impaired myocardial
insulin responsiveness in the progression of heart failure
in advanced age.
Aging has been associated with altered mitochondrial
protein expression and reduced energetic reserve in stud-
ies of skeletal muscle [25,26]. These alterations have been
linked to the cellular mechanisms of insulin resistance,
mediated through increased accumulation of NEFA [4],
features which have been associated with increasedreactive oxygen species production in senescent mito-
chondria [27]. Under conditions in which ROS produc-
tion exceeds anti-oxidative capacity, increased UCP-3
activity dissipates the electromotive force and reduces
mitochondrial ROS production [28]. A consequence of
the decreased transmenbrane potential (Δφ) is reduced
electromotive force for ATP generation, which may
become relevant under circumstances of increased ener-
getic demand, as occurs with pacing induced heart failure
[15,29]. When these physiological adaptive responses are
further compromised by alterations in components of the
electron transfer chain, such as MCO or decreased ex-
pression or function of UCP-3, further ROS generation
leads to lipid peroxidation and eventually mitochondrial
permeability transition, and ultimately necrotic cell
death [7,22].
In the present study we observed myocardial insulin
resistance and altered mitochondrial ROS generation in
association with decreased MCO, and UCP-3 expression
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gles. We focused on IFM as the most relevant compo-
nent given their role in myocardial contractility and
because age-associated changes seem to affect IFM pref-
erentially [30]. Decreased UCP-3 expression would be
expected to further impair the mitochondrial capacity to
mitigate ROS leading to lipid peroxidation and further
mitochondrial dysfunction [31].
We have shown previously that GLP-1 infusion im-
proves cardiovascular function when administered for
48 hours to young dogs with severe dilated cardiomyop-
athy [19]. We have also shown that the hemodynamic
improvement was associated with both increased myocar-
dial glucose uptake and increased expression of key com-
ponents of the mitochondrial electron transport chain
(ETC.), specifically MCO, the expression of which was sig-
nificantly reduced in dilated cardiomyopathy. Further-
more, GLP-1 treatment was associated with reduced
mitochondrial ROS production and increased UCP-3
expression. UCP-3 has been shown to be an important
buffer against excess free radical accumulation within the
mitochondrial matrix (29). We have also shown that
normal aging in older beagles is associated with similar
changes in the absence of heart failure (4). Here, we ob-
serve a similar effect of GLP-1 infusion on UCP-3 and
MCO and also observe better preservation of these com-
ponents following rapid pacing in old animals without
baseline heart failure. Together, these salutary changes in
mitochondrial protein expression were associated with
slowing the progression of heart failure in the GLP-1
treated animals. Thus, both aging and heart failure appear
to be associated with impaired mitochondrial function
and myocardial glucose utilization and the effects appear
to be synergistic.
We have also previously shown that the development
of advanced heart failure in conscious dogs is associated
with impaired coronary flow and vasodilator reserve in
response to coronary vasodilators [20]. Here we demon-
strate that aging alone in the presence of myocardial insu-
lin resistance is associated with impaired coronary flow
reserve in response to sub-maximal doses of adenosine.
Importantly, these data are the first to confirm that GLP-1
treatment improves coronary flow responses to insulin
and adenosine. Furthermore, coronary flow reserve was
better preserved in advanced heart failure in the Old +
GLP-1 compared to Old-Control. This is the first demon-
stration of a vascular protective effect of GLP-1 on coron-
ary flow reserve in a model of non-ischemic DCM.
There is an extensive literature that has demonstrated
the salutary effects of both DPP-4 inhibitors [32] and
DPP-4 resistant long acting receptor analogs [33] in
mitigating ischemia- reperfusion injury and reducing in-
farct size in rodent models through a PKA dependent
mechanism. These findings underscore the importanceof GLP-1 receptor medicated signaling in ischemia-
reperfusion syndromes. Our findings are the first to
document significant salutary effects of GLP-1 (7–36)
amide in a large animal model of aging and heart fail-
ure. The findings are notable in light of the recent clin-
ical trials data that have suggested that DPP-4 inhibitors
increase the risk of heart failure hospitalizations in pa-
tients with Type 2 diabetes [34]. A critical difference is
the fact that in our study, the native peptide is metabo-
lized to the active metabolite, GLP-1 (9–36), which we
[35] have shown to be biologically active, particularly
vasoactive. These additive effects of the metabolite are
not present with DPP-4 inhibitors or DPP-4 resistant
GLP-1 receptor agonists. Secondly, the continuous infu-
sion of the native peptide resulted in steady state
pharmacological concentrations of total GLP-1 (~100
pM) while DPP-4 inhibitors result in physiological
levels (20 pM). These differences may not only be rele-
vant to our findings in older beagles but also explain
why clinical studies of heart failure patients [16] and
post-operative patients [36] have shown benefits with
continuous infusions of the native peptide GLP-1
(7–36) amide.
Limitations
The findings of increased mitochondrial ROS, reduced
mitochondrial protein expression, and impaired myo-
cardial insulin resistance were associations that do not
prove causality in terms of the accelerated course of
DCM in Old-Control. Other cellular process may also
be deranged which could contribute to the response.
Nonetheless, GLP-1 treatment mitigated the mitochon-
drial and metabolic abnormalities and protected Old-
GLP-1against an accelerated course. Secondly, we
measured mitochondrial protein expression not func-
tion. Additional studies detailing mitochondria abun-
dance and morphology may help to further understand
the role of mitochondrial dysfunction in this model and
the extent to which GLP-1 may influence mitochondrial
biogenesis and autophagy. Thirdly, it took several years
to complete this study as the availability of senescent
beagles was rate limiting. We began using MDA as a
method to assess lipid peroxidation and continued to
do so for the purposes of consistency over time. We
recognize that currently there may be better quantita-
tive methods of lipid peroxidation quantification. Fi-
nally, GLP-1 treatment was associated with improved
coronary flow responses, suggesting vascular protective
effects of GLP-1. While we cannot ascertain the relative
contribution of these favorable changes to the improved
clinical outcome in Old + GLP-1 dogs, these data dem-
onstrate that GLP-1 treatment has multiple salutary
cardiovascular effects in heart failure beyond glycemic
control.
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Aging and associated mitochondrial dysfunction and in-
sulin resistance predispose to an accelerated course of
dilated cardiomyopathy and early mortality. Infusion of
GLP-1 (7–36) amide is associated with reduced myocar-
dial mitochondrial ROS and improved myocardial insu-
lin sensitivity and protection against an accelerated
course of dilated cardiomyopathy and early mortality in
older beagles, suggesting salutary cardiovascular effects
in heart failure beyond glycemic control.
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